The entry of nanoparticles into solid tumours
Top Cited Papers
- 1 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Materials
- Vol. 19 (5), 566-+
- https://doi.org/10.1038/s41563-019-0566-2
Abstract
The dominant mechanism of nanoparticle entry into solid tumours has now been shown to be an active trans-endothelial pathway rather than the currently established passive transport via inter-endothelial gaps. The concept of nanoparticle transport through gaps between endothelial cells (inter-endothelial gaps) in the tumour blood vessel is a central paradigm in cancer nanomedicine. The size of these gaps was found to be up to 2,000 nm. This justified the development of nanoparticles to treat solid tumours as their size is small enough to extravasate and access the tumour microenvironment. Here we show that these inter-endothelial gaps are not responsible for the transport of nanoparticles into solid tumours. Instead, we found that up to 97% of nanoparticles enter tumours using an active process through endothelial cells. This result is derived from analysis of four different mouse models, three different types of human tumours, mathematical simulation and modelling, and two different types of imaging techniques. These results challenge our current rationale for developing cancer nanomedicine and suggest that understanding these active pathways will unlock strategies to enhance tumour accumulation.Funding Information
- Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada
- Gouvernement du Canada | Canadian Institutes of Health Research
- Natural Sciences and Engineering Research Council
- Northwell Health
- US Department of Defence, BCRP, Era of Hope Scholar
This publication has 50 references indexed in Scilit:
- Overcoming key biological barriers to cancer drug delivery and efficacyJournal of Controlled Release, 2017
- To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?Journal of Controlled Release, 2016
- Analysis of nanoparticle delivery to tumoursNature Reviews Materials, 2016
- EPR: Evidence and fallacyJournal of Controlled Release, 2014
- Delivering nanomedicine to solid tumorsNature Reviews Clinical Oncology, 2010
- Nanocarriers as an emerging platform for cancer therapyNature Nanotechnology, 2007
- Openings between Defective Endothelial Cells Explain Tumor Vessel LeakinessThe American Journal of Pathology, 2000
- Transport of Molecules, Particles, and Cells in Solid TumorsAnnual Review of Biomedical Engineering, 1999
- Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironmentProceedings of the National Academy of Sciences of the United States of America, 1998
- Microvascular permeability of normal and neoplastic tissuesMicrovascular Research, 1986